Compare Fabrinet (FN) vs Kymera Therapeutics Inc. Common Stock (KYMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Kymera Therapeutics Inc. Common Stock — how do they compare? Fabrinet trades at $382.84 (market cap $15.33B), while Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B). The key difference: Fabrinet is the larger of the two by market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Fabrinet nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 31 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| FN | KYMR | |
|---|---|---|
Market Cap | $15.33B | $8.87B |
Volume | 1,120,187 | 779,107 |
Sector | Technology | Health |
52-Week High | $746.47 | $127.31 |
52-Week Low | $374.91 | $55.80 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $14.46B | $8.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $427.82, down 6.26% in the last session amid broader market volatility. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and robust 45% revenue growth in Q4 2026. Technical indicators present a mixed picture with a bullish overall signal but bearish moving averages, while support levels cluster around $407-$441. The company benefits from surging AI data center demand and capacity expansion initiatives.
Fabrinet's outlook remains positive driven by AI infrastructure growth, though risks include customer concentration and margin pressure. Analysts project 64% upside to the $769.50 consensus target with unanimous bullish sentiment (18 buys, 0 sells). The stock offers exposure to high-growth optical manufacturing but faces execution risks in capital expansion.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →
